<DOC>
	<DOCNO>NCT01908062</DOCNO>
	<brief_summary>The purpose study learn best treat substance use disorder HIV clinic setting . Specifically , purpose pilot study learn extended-release naltrexone ( XR-NTX ) would feasible acceptable treatment HIV-infected individual opioid alcohol use disorder .</brief_summary>
	<brief_title>Comparing Treatments HIV-Infected Opioid Alcohol Users Integrated Care Effectiveness Study</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Meet DSM5 criterion moderate severe opioid use disorder and/or alcohol use disorder . 2 . Be willing randomize antagonistbased therapy TAU treatment opioid and/or alcohol use disorder . 3 . Be HIVinfected defined history positive HIV serology HIV RNA pcr &gt; 10,000 copies/mL ) . 4 . Be willing establish ongoing HIV care CTP already receive ongoing care . 5 . Be willing initiate ART already prescribe ART , regardless CD4 count . 6 . Be least 18 year old . 7 . Be able provide write informed consent HIPAA ( applicable ) medical record abstraction . 8 . Be able communicate English . 9 . If female , willing take measure avoid become pregnant . Individuals exclude pilot study participation : Have serious medical , psychiatric substance use disorder , opinion study physician , would make study participation hazardous participant , compromise study finding , prevent participant complete study . Examples include : 1 . Disabling terminal medical illness ( e.g. , active opportunistic infection , uncompensated heart failure , cirrhosis endstage liver disease , acute hepatitis moderate severe renal impairment ) assess medical history , review system , physical exam and/or laboratory assessment ; 1 . Severe , untreated inadequately treat mental health disorder ( e.g. , active psychosis , uncontrolled manicdepressive illness ) assess history and/or clinical interview ; 2 . Current severe benzodiazepine depressant sedative hypnotic use require medical detoxification ; 3 . Suicidal homicidal ideation require immediate attention . 2 . Have aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) liver enzymes great 5 time upper limit normal screen phlebotomy . Results test conduct within past 30 day abstract medical record information acceptable . 3 . Have INR &gt; 1.5 platelet count &lt; 100k . Results test conduct within past 30 day abstract medical record information acceptable . 4 . Have know allergy sensitivity naloxone , naltrexone , polylactidecoglycolide , carboxymethylcellulose , component VivitrolÂ® diluent . 5 . Anticipate undergoing surgery study participation . 6 . Have chronic pain require ongoing pain management opioid analgesic . 7 . Pending legal action reason might prevent individual completing study . 8 . Currently pregnant breastfeeding . 9 . Body habitus , judgment study physician , preclude safe intramuscular injection XRNTX , ( e.g . excess fat tissue buttock ) . 10 . Received methadone buprenorphine maintenance therapy treatment opioid dependence 4 week prior screen . 11 . Have take investigational drug another study within 30 day study consent . 12 . Have ECG finding , opinion study medical clinician would preclude safe participation study . Results ECGs conduct within past 30 day abstract medical record information acceptable . 13 . Have treatment XRNTX opioid alcohol dependence 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Substance relate disorder</keyword>
	<keyword>HIV</keyword>
	<keyword>naltrexone</keyword>
</DOC>